Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

NCT00831233 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Poor recruitment due to rare targeted population

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix
DRUG: Goserelin
DRUG: Bicalutamide

Sponsor

Ferring Pharmaceuticals